Tracking GBS Antibiotic Resistance in Oceania for Safer Perinatal Care

Streptococcus agalactiae, more commonly called Group B Streptococcus, remains the leading cause of early-onset neonatal sepsis in many high-income countries, and Australia is no exception. While intrapartum antibiotic prophylaxis has dramatically reduced the burden of early-onset disease since the 1990s, the bacteria keep adapting. Clinicians working in tertiary units from the Royal Women's in Parkville to the Mater Mothers' in South Brisbane are increasingly noting unusual susceptibility patterns in routine cultures, and the implications for maternity care are subtle but real. Learn more about リウマチ性疾患と診断されたときの患者教育の進め方.

This article looks at the most recent resistance data emerging from Oceania, with a particular focus on what it means for maternity and neonatal teams across the country. The discussion covers how local surveillance networks are tracking change, what the clinical implications are for penicillin-allergic mothers, and where future research efforts should be directed. The conversation sits at the intersection of microbiology, midwifery, and public health, and it directly affects how families experience one of the most important weeks of their lives. Learn more about 関節位置覚と筋紡錘感覚の基礎.

Resistance Patterns Shifting Across Australian Maternity Units

The backbone of GBS prevention in Australia has been intravenous penicillin G given during labour, with ampicillin as a common alternative. Genuine penicillin allergy is rare in obstetric populations, so most units have used these agents without much difficulty. However, the broader picture of GBS resistance is changing, and clinicians in Sydney, Perth, and Hobart have all reported isolates that test the assumptions baked into older protocols.

Surveillance from the Australian Group on Antimicrobial Resistance (AGAR) has flagged rising non-susceptibility to clindamycin and erythromycin across multiple states. This matters because clindamycin is the standard second-line agent for mothers with a documented penicillin allergy. When the laboratory reports an erythromycin-resistant isolate, the workflow becomes more complex: vancomycin, cefazolin, and lincomycin all enter the conversation, each with its own pharmacokinetic profile in late pregnancy.

Fully penicillin-resistant GBS remains exceedingly rare across the region. The minimum inhibitory concentration creep observed in some European centres has not been mirrored at the same magnitude in Oceania, but the data are still maturing. Local laboratories at Westmead, the Royal Brisbane and Women's, and the Women's and Children's in Adelaide have all contributed to that growing picture, and the picture is one of cautious vigilance rather than alarm.

Comparing Antibiotic Options for GBS Prophylaxis in Late Pregnancy

Different antibiotics carry different resistance profiles, dosing schedules, and neonatal transfer characteristics. The table below summarises the practical considerations that Australian maternity pharmacists typically review when auditing local guidelines.

Microbiological Surveillance Across Oceania

Tracking GBS resistance is not just a laboratory exercise. Networks such as AGAR, the National Neissaria Network, and the Australian and New Zealand Neonatal Network collect isolates from across the country, and the resulting datasets inform the Therapeutic Guidelines and RANZCOG statements on perinatal infection. New Zealand contributes through similar channels, and together the trans-Tasman surveillance offers a clearer regional view than any single hospital could provide.

Beyond the trans-Tasman axis, Pacific Island nations present a different picture. Capacity for routine GBS culture is uneven across Papua New Guinea, Fiji, Samoa, and the Solomon Islands, which means resistance surveillance in those settings is patchy. Regional collaborations supported by the WHO and the Pacific Community have begun to fill the gap, but the data remain sparse. For clinicians who care for mothers who have recently migrated from these settings, that sparsity translates into real uncertainty at the bedside.

Laboratory methods also vary. Some Australian centres now use the more sensitive Granada agar and selective broth techniques recommended by international consensus, while others rely on traditional LIM broth. The choice of method affects both the detection rate and the apparent prevalence of resistance, which is why state-level comparisons should be read with care. A clinician in Darwin may see very different numbers than a colleague in Ballarat, even when the underlying prevalence is similar.

Clinical Implications for Maternity and Paediatric Teams

When the laboratory report shows an unusual susceptibility pattern, the clinical team has to translate that into action very quickly. For most Australian maternity units, the practical playbook now includes a small set of recommendations that have emerged from local and international experience.

• Confirm penicillin allergy with a structured history before defaulting to clindamycin or vancomycin. Many reported allergies are intolerances that do not preclude cephalosporin use.
• Request inducible clindamycin resistance testing (D-test) for any isolate that is erythromycin-resistant but clindamycin-susceptible on initial screening.
• Consider cefazolin for mothers with non-anaphylactic penicillin allergy, especially when the GBS isolate is unavailable, because cefazolin achieves therapeutic levels in the amniotic fluid.
• Reserve vancomycin for documented anaphylactic allergy or confirmed clindamycin-resistant disease, and monitor trough levels in mothers with renal impairment.
• Re-audit local antibiograms every two years, since resistance in a single unit can shift quickly when one clone circulates among labouring women.

For neonatal teams, the early recognition of GBS sepsis and its complications remains essential. Babies who present with lethargy, poor feeding, or seizures require urgent evaluation. Resources such as neonatal seizure and anticonvulsant selection guidance and hypoxic-ischemic encephalopathy cooling therapy criteria help clinicians apply consistent thresholds in the first hours of admission. Respiratory support is another common thread, and teams should review neonatal oxygen therapy targets and weaning strategies regularly so that saturation goals remain aligned with current evidence.

Equity, Indigenous Mothers, and Rural Realities

Antibiotic choice is only part of the story. GBS prevention depends on antenatal detection, and that depends on access to antenatal care. Aboriginal and Torres Strait Islander women in remote parts of the Northern Territory and Western Australia often have to travel hundreds of kilometres for a routine 36-week swab, and the result may not reach the delivering hospital in time. The gap shows up in surveillance data: early-onset GBS rates among Indigenous babies in some regions remain two to three times the national average.

The same issue affects mothers from culturally and linguistically diverse backgrounds, including recent arrivals from the Pacific. Health services in western Sydney, for example, work with a large Tongan and Samoan community, and the communication of GBS results needs to be paired with appropriate interpreters. Translating microbiological information into plain language is not glamorous work, but it is the difference between a mother who understands why she is receiving antibiotics in labour and one who simply endures the drip.

Models of care that have shown promise include community-led midwifery outreach, point-of-care GBS PCR testing in smaller rural hospitals, and shared antenatal records that travel with the mother. The Kimberley region has trialled some of these approaches with support from the WA Country Health Service, and early feedback has been encouraging. The challenge is to scale them without losing the cultural safety that makes them work.

Patient education itself is an underappreciated lever. The conversations clinicians have at 34 weeks, when a swab result lands, shape whether a mother will accept intrapartum antibiotics. Drawing on frameworks for patient education when a diagnosis is delivered can be surprisingly useful, since the emotional and informational needs are often shared across diagnostic categories. The goal is the same: a mother who feels informed, not overwhelmed.

Future Research and Cross-Border Collaboration

The next chapter in Oceania GBS work will likely focus on three areas. The first is maternal vaccination, with several candidate vaccines in late-stage trials that could one day replace the current screen-and-treat paradigm. The second is rapid molecular diagnostics, which shorten the time between swab and result from days to hours, particularly valuable in rural and remote settings. The third is genomic surveillance, which can distinguish between sporadic resistance and the spread of a single clone across multiple jurisdictions.

For Australian researchers, the opportunity is to build stronger ties with Pacific colleagues. Joint studies in Fiji and Samoa could provide the data needed to design context-appropriate guidelines for low-resource settings, rather than exporting metropolitan protocols wholesale. The Perinatal Society of Australia and New Zealand and the Australasian Society for Infectious Diseases have both signalled interest, and recent grant rounds from the NHMRC have begun to recognise the value of regional partnerships.

A small but growing body of work also examines the longer-term neurodevelopmental outcomes of infants who survive GBS meningitis. Some of these babies have subtle motor and sensory differences that only become apparent in the preschool years, and a better understanding of proprioception and motor learning could improve follow-up. Materials on the foundations of joint position sense and muscle spindle function provide a useful primer for clinicians who are building assessment pathways and want to revisit the physiology behind sensorimotor development.

Explore the related stories and resources across the FAOPS 2020 archive, and keep the conversation going with colleagues across Oceania. The next advance in GBS prevention will come from shared learning, and each unit's contribution matters — from the largest tertiary centre in the eastern capitals to the smallest remote clinic in the Torres Strait.